Optiver Holding
MLYS icon

Optiver Holding’s Mineralys Therapeutics MLYS Stock Holding History

Optiver Holding’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.17K Buy
80
+38
+90% +$1.11K ﹤0.01% 1812
2025
Q4 		$1.52K Sell
42
-244
-85% -$9.79K ﹤0.01% 2118
2025
Q3 		$10.8K Buy
+286
New +$6.19K ﹤0.01% 1248

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Optiver Holding's MLYS Position: Q1 2026 in Review

Optiver Holding increased its Mineralys Therapeutics (MLYS) stake by 90% in Q1 2026, buying an estimated $1.11K and bringing the position to 80 shares worth $2.17K. The position accounts for ﹤0.01% of the portfolio, ranked #1812.

Optiver Holding first reported a position in MLYS in Q3 2025 and has held it in 3 quarters since. The position peaked at $10.8K in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Optiver Holding held 80 shares of Mineralys Therapeutics worth $2.17K as of Q1 2026.
  • Optiver Holding bought 38 Mineralys Therapeutics shares in Q1 2026, an estimated $1.11K.
  • Mineralys Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1812 holding.
  • Optiver Holding first reported a position in Mineralys Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Optiver Holding's Mineralys Therapeutics position peaked at $10.8K in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.